Biotech Catalysts This Week: FDA Decisions, Readouts & Earnings (Jun 21–Jun 28, 2026)

· 1 min read

Here’s what’s on the biotech calendar for June 21–June 28: 0 FDA decision dates, 0 trial catalysts, and 0 earnings reports from tracked companies.

📡 Run-up Radar Highlights

Stocks entering the pre-catalyst window with the strongest setups (full radar is a Premium feature):

  • UNCY — NDA in 8 days, score 84/100
  • CELC — NDA in 26 days, score 66/100
  • CORT — NDA in 20 days, score 62/100

📈 Last Week’s Biggest Gainers

  • QURE +78.44% (volume 11.2x average)
  • BFLY +55.87% (volume 12.1x average)
  • BRAI +54.20% (volume 6.4x average)
  • RXT +33.17% (volume 2.7x average)
  • XNDU +18.24% (volume 1.3x average)

Track your tickers on the BioRadar dashboard →

This digest is for informational purposes only and is not investment advice. Always do your own research.

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.